tradingkey.logo
搜索

LivaNova PLC

LIVN
添加自选
71.740USD
+1.650+2.35%
收盘 05/12, 16:00美东报价延迟15分钟
3.92B总市值
36.28市盈率 TTM

LivaNova PLC

71.740
+1.650+2.35%
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+2.35%

5天

+21.45%

1月

+14.27%

6月

+36.18%

今年开始到现在

+16.59%

1年

+62.82%

TradingKey LivaNova PLC股票评分

单位: USD 更新时间: 2026-05-11

操作建议

LivaNova PLC当前公司基本面数据相对非常健康,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在医疗设备与耗材行业排名3/206位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价80.22。中期看,股价处于平稳状态。近一个月,市场表现较强,技术面和基本面综合得分较高,较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

LivaNova PLC评分

相关信息

行业排名
3 / 206
全市场排名
42 / 4492
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
看空

LivaNova PLC亮点

亮点风险
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
业绩高增长
公司营业收入稳步增长,连续3年增长20.33%
业绩转亏
公司业绩转亏,最新年度亏损美元
估值合理
公司最新PE估值35.45,处于3年历史合理位
机构减仓
最新机构持股60.49M股,环比减少15.69%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓,最新持仓市值11.00

分析师目标

根据 11 位分析师
买入
评级
80.222
目标均价
+11.64%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

LivaNova PLC新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

LivaNova PLC简介

LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
公司代码LIVN
公司LivaNova PLC
CEOMakatsaria (Vladimir A)
网址https://www.livanova.com/
KeyAI